

Novacyt S.A.

("Novacyt" or the "Company")

Conversion of Loan Notes

Paris, France and Camberley, UK – 3 May 2019 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme ("Agreement") announced on 23 April 2019, it has issued two tranches of new ordinary shares of €1/15 each ("Ordinary Shares") to Negma Group Limited ("Negma") following the receipt of two conversion notices. Further details are set out below.

Conversion notice dated: 26 April 2019

| | |
|--|---------|
| Number of Notes converted | 1 |
| Conversion amount | €2,500 |
| Lowest VWAP during the 15 days preceding the conversion notice | €0.1880 |
| Conversion price | €0.16 |
| Number of shares issued | 15,625 |

Conversion notice dated: 2 May 2019

| | |
|--|---------|
| Number of Notes converted | 7 |
| Conversion amount | €17,500 |
| Lowest VWAP during the 15 days preceding the conversion notice | €0.1803 |
| Conversion price | €0.15 |
| Number of shares issued | 116,666 |

Application will be made for the 132,291 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on 10 May 2019.

In addition, pursuant to the terms of the Agreement, the Company has issued Negma 74 convertible loan notes for a total amount of €185,000 in settlement of the arrangement fee of 3.7% of the €5million facility due upon the initial drawdown of €2million by the Company.

Total Voting Rights

Following Admission, the total number of ordinary shares in the Company is 37,796,632. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

For further information, please refer to www.novacyt.com or contact:

- End -

Contacts

Novacyt SA

Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472

SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)

Matthew Johnson / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

WG Partners (Joint Broker)

Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330

FTI Consulting (International)

Brett Pollard / Victoria Foster Mitchell/ Mary Whittow
+44 (0)20 3727 1000

brett.pollard@fticonsulting.com/victoria.fostermitchell@fticonsulting.com/
Mary.whittow@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51

arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high quality assays and reagents worldwide. The Group directly serves oncology, microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com